Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium‑induced contraction, leading to vasodilation of brain vessels, enhanced cerebral perfusion, and a lower chance of vasospasm‑related ischemia.

The dosage of Nimotop is individualized by the treating physician based on the patient’s clinical condition, age, renal and hepatic function, and concomitant therapies. Prescribers determine the appropriate strength, frequency, and duration for each patient.

Safety data for nimodipine in pregnancy and lactation are limited. It is generally avoided unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimodipine is distinguished by its high affinity for cerebral vessels and its ability to cross the blood‑brain barrier, making it especially effective for preventing vasospasm after subarachnoid hemorrhage. Other calcium channel blockers, such as amlodipine or nifedipine, are primarily used for systemic hypertension and lack the same degree of cerebral selectivity.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Nimotop is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, jaundice, or signs of an allergic response.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those taking interacting medications that could lead to dangerous blood‑pressure drops.